Anaptysbio (ANAB) Income from Continuing Operations (2016 - 2026)
Anaptysbio (ANAB) posted Income from Continuing Operations of 52884000.0 for Q1 2026, down 205.29% on a QoQ basis from 50227000.0 in Q4 2025, and down 34.47% year-over-year from 80696625.9 in Q1 2025.
Anaptysbio (ANAB) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Anaptysbio's Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 52884000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 34.47% year-over-year to 52884000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26174000.0 (up 76.23% YoY) and the FY2025 annual result came in at 12619000.0, up 89.0% from the prior year.
- Income from Continuing Operations was 52884000.0 for Q1 2026 at Anaptysbio, down from 50227000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 50227000.0 in Q4 2025 and bottomed at 62550000.0 in Q1 2023.
- A 5-year average of 31170470.59 and a median of 39329000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 94.94% — and 2025, when it soared 476.2%.
- Anaptysbio's Income from Continuing Operations stood at 22718000.0 in 2022, then tumbled by 85.61% to 42168000.0 in 2023, then jumped by 120.67% to 8717000.0 in 2024, then surged by 476.2% to 50227000.0 in 2025, then plunged by 205.29% to 52884000.0 in 2026.
- Business Quant data shows ANAB's Income from Continuing Operations at 52884000.0 in Q1 2026, 50227000.0 in Q4 2025, and 15113000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Anaptysbio | 1.55 Bn | 1.27 Bn | - | -52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.88 Mn |
| Dec 31, 2025 | 50.23 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.63 Mn |
| Mar 31, 2025 | -39.33 Mn |
| Dec 31, 2024 | 8.72 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.66 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | -42.17 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -62.55 Mn |
| Dec 31, 2022 | -22.72 Mn |
| Sep 30, 2022 | -37.62 Mn |
| Jun 30, 2022 | -51.08 Mn |
| Mar 31, 2022 | -56.38 Mn |
| Dec 31, 2021 | -32.13 Mn |
| Sep 30, 2021 | -33.69 Mn |
| Jun 30, 2021 | -26.20 Mn |